Express Pharma

APRIL 22, 2024

Despite the ongoing uncertainties surrounding macroeconomic activities, fluctuating interest rates, and changes in the Medicare Drug Price Negotiation landscape, the top 20 global biopharma companies experienced a promising first quarter this year. trillion as on 31 December 2023 to $4 trillion as on 31 March 2024, reveals GlobalData.

Drug Pricing 102

Drug Pricing Diabetes Vaccines 102

pharmaphorum

APRIL 13, 2022

The treatment has been around for over a century but insulin has still become the centre of the ongoing discussion over pricing of pharmaceutical products. Ben Hargreaves looks at why insulin’s price is so controversial and whether this could be set to change. In the US, approximately 37.3 In the US, approximately 37.3

Drug Pricing 130

Drug Pricing Diabetes Biosimilars 130

STAT

AUGUST 10, 2023

supplies of starter doses of its hugely popular Wegovy weight-loss drug, most likely into 2024, as the company struggles to keep up with soaring U.S. The company is riding a wave of sky-high demand for its highly effective diabetes and weight-loss drugs, Ozempic and Wegovy, but will extend the limits introduced for Wegovy supplies.

Drug Pricing 183

Drug Pricing Diabetes 183

STAT

MARCH 14, 2023

list prices for several insulin products by up to 75%, the latest big drugmaker to take such a step in response to a years-long outcry over the cost of the diabetes treatments. The company plans to cut the list price of its NovoLog insulin by 75%, and the prices for Novolin and Levemir by 65% starting in January 2024.

Diabetes 242

Diabetes Drug Pricing 242

Express Pharma

FEBRUARY 21, 2024

The top 20 global biopharmaceutical companies experienced varied year-on-year (YoY) market capitalisation shifts in 2023 amid the macroeconomic headwinds, steep patent cliffs and the commencement of US drug price negotiations under the Inflation Reduction Act (IRA). Nonetheless, there was a resilient upturn of 1.6

Drug Pricing 90

Drug Pricing Diabetes Biosimilars 90

STAT

JULY 6, 2023

Advertisements eviscerating and glorifying pharmacy benefit managers have been around for years, but have intensified over the past three months as Congress scrutinizes the role these middlemen play in shaping high prescription drug prices , STAT tells us. in 2024. The company hopes to launch the product in the U.S.

Drug Pricing 154

Drug Pricing Vaccines Diabetes Pharmaceutical Companies 154

pharmaphorum

JANUARY 13, 2023

.” He added that people from low-income households and some racial and ethnic groups are disproportionately impacted by the practices, including Hispanic and Black people, who are much more likely to be diagnosed with diabetes than non-Hispanic white people – and much more likely to die as a result of complications.

Diabetes 105

Diabetes Drug Pricing Biosimilars 105